Table 3 The prevalence of FOG in Parkinson’s disease reported in these literatures

Margolesky et al [36]

26.5% (27/102)

Mckay et al [46]

40.0% (26/65)^c

33.3% (15/45)

55.0% (11/20)

Mancini et al [40]

26.6% (25/94)^a

Djaldetti et al [37]

34.8% (15/41)

34.8% (15/41)

Ehgoetz Martens et al [38]

41.6% (92/221)

Kader et al [44]

56.8% (138/243)^a

Sutter et al [45]

41.4% (46/111)^a

37.0% (34/92)

63.2% (12/19)

Forsyth et al [43]

39.0% (30/82)^a

Ricciardi et al [41]

55.8% (24/43)*

Vervoort et al [42]

22.4% (17/76)^a

Shin et al [35]

38.6% (54/141)

29.2% (21/73)

48.4% (31/64)

59.1% (13/22)

Allen et al [21]

49.4% (114/231)

Amboni et al [11]

54.8% (325/593)^a

27.4% (48/175)

65.8% (271/412)

78.3% (148/189)

35.3% (124/351)

82.9% (194/234)

Forsaa et al [22]

27.2% (63/232) ^b

62.5% (145/232)

Gazibara et al [23]

36.7% (110/300)

Lieberman et al [24]

12.7% (27/212)

Lindholm et al [25]

41.1% (58/141)^a

Walton et al [26]

42.4% (86/203) ^a

Bohnen et al [8]

14.0% (20/143)

Ou et al [27]

46.6% (221/474) ^a

36.1% (108/299)

64.6% (113/175)

33.5% (115/343)

82.2% (106/129)

Perez-Lloret et al [28]

38.2% (257/672) ^b

25.4% (85/335)

51.0% (172/337)

31.5% (174/553)

60.0% (150/250)

Auyeung et al [10]

86.5% (148/171)

Contreras et al [29]

44.4% (71/160)^a

Garcia-Ruiz et al [30]

4.4% (2/45)

44.4% (20/45)

68.9% (31/45)

Josiah et al [31]

41.5% (380/916)^b

Coelho et al [32]

62.0% (31/50)

62.0% (31/50)

Moore et al [9]

55.1% (65/118) ^a

Giladi et al (2001)

7.1% (57/800)

Giladi et al (2001)

53.5% (92/172)

22.2% (10/45)

63.8% (81/127)